Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

US Patent Issued - BARD1 Patent Family Lung Cancer Diagnosis (ASX:IIQ)

US Patent No 11137402 granted covering lung cancer diagnosis Protects a BARD1 autoantibody test for diagnosis of lung cancer in key US market Melbourne, Australia, 12 November 2021: BARD1 Life...read more

BARD1 Life Sciences - EXO-NET ANZSEV Presentation (ASX:IIQ)

To view the presentation, download the attached PDF.

BARD1 Life Sciences Presenting at Bell Potter Healthcare Conference (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that BARD1 CEO Dr Leearne Hinch will be delivering the enclosed presentation to the Bell Potter Healthcare Confere...read more

BARD1 Life Sciences - EXO-NET Presented at Virtual ANZSEV Symposium (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to announce that Dr Emily Stein, BARD1 Technology Director and founding scientist of the Molecular Nets technology, will be pr...read more

BARD1 Life Sciences - Jobkeeper Payment Notification (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), provides this market announcement in accordance with subsection 323DB(1) of the Corporations Act 2001. Listed entities are required t...read more

BARD1 Life Sciences - Notice of Annual General Meeting/Proxy Form (ASX:IIQ)

You are invited to attend the 2021 Annual General Meeting (AGM) of BARD1 Life Science Limited (BARD1), which is scheduled to be held at 2:00pm (AEDT) on 29 November 2021 (Meeting). Due to the contin...read more

BARD1 Life Sciences - Ceasing to be a substantial holder (ASX:IIQ)

To view the notice, download the attached PDF.

BARD1 Life Sciences - Appendix 4G and Corporate Governance Statement (ASX:IIQ)

To view the appendix, download the attached PDF.

BARD1 life Sciences - Appendix 4C & Quarterly Activities Report (ASX:IIQ)

Commercial progress: -- hTERT receipts of $221k for the period compared to $184k for the previous quarter -- EXO-NET® RUO evaluations progress with academic and industry partners -- BARD1 au...read more

BARD1 Life Sciences - Change of Director's Interest - Philip Powell (ASX:IIQ)

To view the Change of Director’s Interest Notice, download the attached PDF.

BARD1 Life Sciences - Amended Remuneration Table Directors Report (ASX:IIQ)

The Company released its 2021 Annual Report on 29th September 2021. Subsequent to release, a typographical error was discovered in the ‘Remuneration of Key Management Personnel’ table wi...read more

BARD1 Life Sciences - Notice required under listing rule 3.13.1 (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company), advises that the Annual General Meeting is currently scheduled for 29 November 2021. The closing date for the receipt of nominations fro...read more

BARD1 Life Sciences - Notification of cessation of securities (ASX:IIQ)

To view the Notification of cessation of +securities, download the attached PDF.

BARD1 Life Sciences - 2021 Annual Report (ASX:IIQ)

BARD1 Life Sciences Limited (ASX:BD1) (BARD1 or the Company) is pleased to release its Annual Report for the 2021 financial year. The Company reported a loss for the year of $12.327m when the App...read more

BARD1 Life Sciences Appoints New CSO (ASX:IIQ)

BARD1 appoints eminent medical researcher Dr Greg Rice as Chief Scientific Officer (CSO) to accelerate the commercial development of its diagnostic tests Dr Rice has extensive commercial and acad...read more

Viewing: 76 - 90 of 111 Previous | Next